Morgan Ebert is managing editor of Contemporary OB/GYN® and Contemporary Pediatrics®. She joined the MJH Life Sciences team in December 2019. She graduated from Youngstown State University in 2019 with a bachelor's degree in journalism and a minor in political science. Prior to graduating, Morgan worked as the editor-in-chief of her college newspaper. She went on to work as an assignment editor at a broadcast news station in Youngstown, Ohio, before joining the Contemporary brands. You can reach her at mebert@mjhlifesciences.com.
Study authors from a poster highlighted at the 2023 Society of OB/GYN Hospitalists Annual Clinical Meeting suggest that implementing a standardized oxytocin infusion protocol may increase patient safety, while simultaneously reducing the rate of postpartum hemorrhage.
In a poster featured at the 2023 Society for OB/GYN Hospitalists Annual Clinical Meeting, study investigators underline the importance of aesthetics in cesarean section closures as both providers and patients.
Sadia Haider, MD, MPH, talks about the latest guidelines from the Society of Family Planning regarding contraception for trans patients, RH testing during pregnancy, and Depo-Provera self-administration at the 2023 ACOG Annual Clinical and Scientific Meeting.
In this video interview, experts provide a synopsis of their presentation about technology and obstetric care at the 2023 ACOG Annual Clinical and Scientific Meeting.
At the 2023 ACOG Annual Clinical and Scientific Meeting, Haywood Brown, MD, discusses the current maternal mortality rate in the United States, as well as disparities affecting different racial and ethnic groups.
Anne Banfield, MD, discusses the highlights from her presentation on primary HPV screening at the 2023 ACOG Annual Clinical and Scientific Meeting in Baltimore, Maryland.
Genevieve Neal-Perry, MD, PhD, talks about the recent approval of fezolinetant (Veozah; Astellas Pharma) and her latest phase 3 research presented at the 2023 ACOG Annual Clinical and Scientific Meeting.
Fezolinetant (Veozah; Astellas Pharma) is now the first neurokinin 3 receptor antagonist approved for the treatment of vasomotor symptoms associated with menopause.
At the 2023 Pediatric Academic Societies Meeting, presenters provided the benefits of breastfeeding, along with some useful tips for lactation and how to best help your breastfeeding patients.
Jonathan Miller, MD, pediatrician and chief of primary care, pediatrics, at Nemours Children's Health in the Delaware Valley, spoke about the latest data regarding early HPV vaccination in children as young as 9 at the 2023 Pediatric Academic Societies meeting.
Yasaswi Kislovskiy, MD, MSc, ob-gyn and reproductive infectious disease specialist, Allegheny Health Network, Pittsburgh, Pennsylvania, discusses the stigma around STDs/STIs and how clinicians can help spread awareness amongst their patients and their community.
Following voluntary market withdrawal from Covis Pharma, the FDA has decided to withdraw the approval of Makena and its generics for reducing the risk of preterm birth.
To close out Endometriosis Awareness Month in March, Rachel Cullifer, MD, discusses clinical pearls for diagnosis and treatment, as well as some common misconceptions about endometriosis.
In honor of Women's History Month, Beth Prairie, MD, MPH, chief medical officer, West Penn Hospital, shares her experience as a female in medicine and as a woman in leadership.
Millicent McCarren, MD, of Allegheny Health Network, sits down with Contemporary OB/GYN® to discuss tips, tricks, and clinical pearls for making sure your adolescent patients are coming in for their routine well woman visits.
Newly published data from a phase 3 study demonstrate the safety and efficacy of fezolinetant (Astellas) for treatment of VMS due to menopause.
In the study, investigators analyzed the Jada System in 800 patients from October 2020 to April 2022 across 16 hospitals in the United States. Results of the study were presented at the SMFM 43rd Annual Pregnancy Meeting in San Francisco, California.
A single oral dose of azithromycin in women in labor planning vaginal delivery significantly reduced the risk of maternal death and sepsis, according to study results presented at the SMFM 43rd Annual Pregnancy Meeting.
The US Food and Drug Administration has accepted the Biologics License Application (BLA) for a proposed biosimilar of denosumab (Prolia and Xgeva; Amgen) for treatment of various conditions.
In this interview, Michael Krychman, MD, a community-based gynecologist in Newport Beach, California, takes a look at 2022 advances within the contraceptive space, as well as looks toward the future.
The American Association of Gynecologic Laparoscopists (AAGL) held its 51st Global Congress on minimally invasive gynecologic surgery (MIGS) in Aurora, Colorado, from December 1 to 4, 2022.
Marco Taglietti, MD, president and CEO of Scynexis, sits with Contemporary OB/GYN® to discuss the recent approval of ibrexafungerp (Brexafemme) for the reduction in incidence of recurrent vulvovaginal candidiasis.
Ibrexafungerp (Brexafemme; Scynexis) is now approved for the treatment of vulvovaginal candidiasis and reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC).
Sarah Crafton, MD, details how sentinel lymph node mapping can help identify the stage of uterine cancers and lead to better patient care.
Jeanette Carpenter, MD, MSCI, maternal-fetal medicine specialist at Pediatrix Medical Group, discussed a recently published study regarding pregnant COVID-19 patients who also had disseminated intravascular coagulation (DIC).
In this bonus episode, Nash Moawad, MD, MS, FACOG, FACS, sits down to discuss the recent standardization of Essentials of Minimally Invasive Gynecologic Surgery (EMIGS) training program for minimally invasive gynecologic surgeons and how it's shaping the way this subspecialty delivers care.
This is the first FDA-approved ADC for platinum-resistant disease, according to ImmunoGen.
Tracey Vogel, MD, of the Allegheny Health Network, discusses the organization's new Perinatal Trauma-informed Care Clinic, as well as some useful tips for implementing trauma-informed care into your own practice.
Alyssa Dweck, MD, discusses some recent positive data presented at the 2022 NAMS meeting regarding Clairvee (Bonafide Health) as a potential treatment for vaginal odor.
Houston, Texas, was buzzing with the latest updates in women’s health at the 25th Annual Nurse Practitioners in Women’s Health Premier Women’s Healthcare Conference held from September 29 to October 2, 2022.
